Patterns and Incidence of Pneumonitis and Initial Treatment Outcomes with Durvalumab Consolidation Therapy after Radical Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer

Patterns and Incidence of Pneumonitis and Initial Treatment Outcomes with Durvalumab Consolidation Therapy after Radical Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer

Durvalumab consolidation after chemoradiotherapy for stage III non-small cell lung cancer (NSCLC) has become the standard of care. Single-center results were examined for treatment outcomes and patterns of pneumonitis in clinical practice. Patients with stage III NSCLC who underwent chemoradiotherap...

Full description

Bibliographic Details
Main Authors: Mizuki Sato, Kazumasa Odagiri, Yuya Tabuchi, Hiroaki Okamoto, Tsuneo Shimokawa, Yukiko Nakamura, Masaharu Hata
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Cancers
Subjects:
chemoradiotherapy
durvalumab
non-small cell lung cancer
immune checkpoint inhibitors
radiation pneumonitis
adverse effects
Online Access:https://www.mdpi.com/2072-6694/16/6/1162

Internet

https://www.mdpi.com/2072-6694/16/6/1162

Similar Items